Digest Network Come funziona
Network
/
Società
Te
Non verificato

Teva Pharmaceutical Industries Ltd

Di cosa scriviamo

Annunci EconomiciFarmaceuticaFinanzaManagement/Organizzazione AziendaleMedicina Salute Benessere

37 comunicati stampa

Guarda tutti i comunicati
07/04/2025
Farmaceutica
Medicina Salute Benessere
Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1,00
0
31/03/2025
Farmaceutica
Annunci Economici
New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1,00
0
27/03/2025
Farmaceutica
Management/Organizzazione Aziendale
Teva Releases Q1 2025 Aide Memoire
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1,00
0
27/03/2025
Farmaceutica
Management/Organizzazione Aziendale
Teva Releases Q1 2025 Aide Memoire
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1,00
0
27/03/2025
Farmaceutica
Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1,00
0
03/03/2025
Farmaceutica
Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1,00
0
27/02/2025
Farmaceutica
Annunci Economici
2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1,00
0
21/02/2025
Farmaceutica
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1,00
0
Press Release cover image
21/02/2025
Farmaceutica
Medicina Salute Benessere
Les besoins du patient au centre de toutes les priorités : pourquoi l’Europe doit agir pour protéger l’accès aux médicaments ?
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1,00
0
21/02/2025
Farmaceutica
Medicina Salute Benessere
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1,00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0